drugset / Trial / NCT03869905

Aquamin® as an Adjuvant Intervention for Ulcerative Colitis

NCT03869905

Phase 2 Active not recruiting 40 enrolled Muhammad N Aslam, MD
RandomizedParallel-groupTriple-blindSupportive care

Summary

The purpose of this study is to determine if Aquamin® works as a potential treatment to improve symptoms and if it will induce remission in patients with mild Ulcerative Colitis and extend remission in Ulcerative Colitis in remission.

Timeline

Start
2019-08-08
Primary completion
2027-12
Completion
2027-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Aquamin Other / unclassified 800 mg

Indications